Clinical efficacy and safety of 60%-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy

Authors: Dong Daoquan,  Dong Yingli,  Wang Zhili,  Li Shuyin,  Cui Longjiang,  Niu Chao,  Chen Xiao
DOI: 10.3760/cma.j.issn.2095-0160.2015.10.017
Published 2015-10-10
Cite as Chin J Exp Ophthalmol, 2015,33(10): 945-948.

Abstract                             [Download PDF] [Read Full Text]

Background

It is thought in recently that photodynamic therapy (PDT) is an effective treatment method for chronic central serous chorioretinopathy (CSC), but the dosage of verteporfin and its long-term efficacy and complications is rarely elucidated ever before.

Objective

This study was to observe the long-term efficacy and safety of 60% dose verteporfin PDT for chronic CSC.

Methods

This is a retrospective study and a self-controlled design was used.The clinical data of 25 eyes of 21 chronic CSC patients who received 60%-dose verteporfin PDT in Henan Eye Institute from January 2009 to May 2010 were reviewed, with the male 18 (85.71%) and female 3 (14.29%) as well as monocular CSC 17 patients and binocular CSC 4 patients.The average ages of the patients were (43±5) years.Fundus fluorescein angiography (FFA), indocyanine green angiography(ICGA), optical coherence tomography(OCT) and best corrected visual acuity (BCVA) were examined in all the patients before and after treatment.PDT with the 60%-dose verteporfin (3.6 mg/m2) was carried out on the CSC eyes.The treated eyes were examined 2 weeks, 1 month and 3 months after PDT.The BCVA, subfoveal choroid thickness, FFA and ICGA findings before and after PDT were compared.The following-up duration was 5 years or more.

Results

The BCVA before and 3 months after PDT were 0.5±0.1 and 0.9±0.2, respectively, with a statistically significant difference between them (t=19.17, P=0.00). The subfoveal choroidal thickness value 3 months after PDT was (326.56±39.47) μm, which was significantly reduced in comparison with (486.24±47.53) μm before PDT (t=25.17, P=0.00). FFA and ICGA showed that the leakage of fluorescein (hyperfluorescence) was disappeared in all the treated eyes.No systemic or local adverse effects and recurrence were observed during the follow-up period.

Conclusions

On the basis of the results of this study and available information, 60%-dose verteporfin PDT seems to have a better long-term efficacy and safety than full-dose verteporfin in treating chronic CSC.

Key words:

Central serous chorioretinopathy/therapy; Photochemotherapy; Verteporfin/dosage; Fundus fluorescein angiography; Indocyanine green; Tomography, optical coherence; Visual acuity

Contributor Information

Dong Daoquan
Henan Eye Institute, Henan Eye Hospital, Zhengzhou 450003, China
Dong Yingli
Wang Zhili
Li Shuyin
Cui Longjiang
Niu Chao
Chen Xiao
(Read 11 times, 1 visits today)
Updated: March 1, 2023 — 2:24 am